Within Range: Demystifying Diabetes Tech for Healthcare Professionals

Insulet International
  • 5.0 (4)
  • Medicine

Within Range is a podcast for Healthcare Professionals. Diabetes tech innovation moves quickly and it can be challenging to keep all the details about the available AID systems straight. Our new podcast, Within Range: Demystifying Diabetes Tech will help bust some myths and clear up any confusion about the Omnipod® 5 Automated Insulin Delivery System. Co-hosts Cindy Pickering & Kate Neal lead conversations with Healthcare Professionals with varying specialties and backgrounds. From clinical research and guidelines, system details, algorithm functionality, to the more practical aspects of helping people live with T1D, you are invited to listen in, while they cover a variety of specialisms. This professional (but entertaining) podcast aims to navigate the complexities of diabetes technology and increase understanding and confidence to help simplify diabetes management for your patients using the Omnipod 5 Automated Insulin Delivery System.

  1. 11 Aug

    How Omnipod Discover™ Can Simplify Data Management for HCPs

    Getting patients connected, reviewing data efficiently, and turning insights into meaningful action are some of the biggest challenges facing healthcare professionals using diabetes technology today. How can a data management platform make patient care simple, fast, and effective? In this episode of Within Range: Demystifying Diabetes Tech, Kate Neal, JD, Clinical Services Manager at Insulet, is joined by Cari Berget, RN, CDCES, from the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine, to explore Omnipod Discover, Insulet’s new data management platform designed to support healthcare professionals and people living with diabetes. Together, Kate and Cari discuss what makes effective diabetes data management so important, how Omnipod Discover™ simplifies onboarding and report review, and why features such as insights and streamlined reporting can help both clinicians and patients make more informed decisions. They also explore the latest updates to the widely used PANTHERTOOLS®, practical approaches to patient empowerment, and how healthcare professionals can help people living with diabetes engage more confidently with their data. Cari also shares real-world patient stories that highlight how access to clear, actionable data can uncover barriers to care and improve confidence with Automated Insulin Delivery (AID) systems.    Whether you're supporting people new to diabetes technology or looking to optimise outcomes for existing users, this episode offers practical insights into how data can strengthen the partnership between healthcare professionals and patients. --- How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations. Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D). If you’re looking to improve your knowledge and understanding of AID and Omnipod 5, then this is the podcast for you. --- Disclaimer This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System, Omnipod Discover™ and its use within​ clinical practice settings. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/sscp for complete safety information including indications, contraindications, warnings, cautions, and instructions. Omnipod 5 may not be available in your country. Refer to the Omnipod Discover Data Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.   © Insulet Corporation. All rights reserved. INS-OHS-06-2026-00113 v1.0

  2. 7 Jul

    ATTD 2026 Clinical Data Recap: Exciting New Data with Omnipod 5

    Reviewing key data presented at the 2026 Advanced Technologies & Treatments for Diabetes (ATTD), Within Range unpacks the latest real-world evidence & outcomes of various studies and analyses within the type 1 diabetes (T1D) population. Host Cindy Pickering, Clinical Services Manager at Insulet, is joined by Kellee Miller and Alex Nguyen, two senior leaders from Insulet's Medical Affairs team, to break down what the data means for healthcare providers (HCPs) and their patients. Kellee and Alex walk through a real-world analysis of over 176,000 Omnipod 5 users across the US, UK, Germany and France, revealing which optimised settings are most strongly associated with achieving greater than 70% time in range (TIR) - without increasing hypoglycaemia. Kellee and Alex also share results from the largest real-world analysis study of insulin pump persistence conducted in France and a recent health outcomes economics study explores how Omnipod 5 users are experiencing fewer hypoglycaemia-related emergency room visits compared with other Automated Insulin Delivery Systems (AIDs). --- How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations. Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D). If you’re looking to improve your knowledge of AID and Omnipod 5, then this is the podcast for you. --- Disclaimer Note: The information in this podcast is accurate to the date of recording as of 30/03/2024.  Kelle Miller, Alex Nguyen and Cindy Pickering are employees of Insulet but their views and opinions expressed in this podcast are their own and do not necessarily reflect those of Insulet.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings.  The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/sscp for complete safety information including indications, contraindications. Omnipod 5 may not be available in your country.  INS-OHS-04-2026-00317 v1.0

  3. 23 Jun

    Early Adoption of Diabetes Technology & Why Its Important

    Early CGM and AID adoption in type 1 diabetes: what happens when you start from day one instead of waiting? Kate Neal, Clinical Services Manager at Insulet, is joined by Dr Halis Kaan Akturk from the Barbara Davis Centre for Diabetes in the US to unpack how early initiation of CGM and AID is changing and improving outcomes for patients. In his clinic, CGM is introduced at diagnosis, with many patients moving onto AID within the first few months. Drawing on large cohort studies, Dr Akturk explains how starting in the first three months leads to lower A1C, fewer severe hypoglycaemic events, and reduced risk of DKA, with those improvements sustained over time. The conversation also explores recent guideline updates from the American Diabetes Association, which now place a much stronger emphasis on early access to diabetes technology rather than delaying adoption. Alongside the data, this episode gets into the reality of making it work. From first visit CGM starts and remote follow ups, to using simplified bolusing and custom targets, Dr Akturk shares how his team meets patients where they are and removes barriers to getting started. You will also hear how systems like Dexcom G7 and Omnipod® 5 Automated Insulin Delivery System are being used day to day to make diabetes management less burdensome. -   Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod® 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D). ​If you’re looking to improve your patient’s time in range as well as time in happiness, then this is the podcast for you. ​       Disclaimer​:    Note: The information in this podcast is accurate to the date of recording as of 12/03/2026. Dr Akturk, ​views and opinions expressed in this podcast are his own and do not necessarily reflect those of Insulet. ​   Though the Omnipod 5 System is safe to use at atmospheric pressures typically found in airplane cabins during flight, the atmosphere pressure in an airplane cabin can change during flight, which may affect the Pod's insulin delivery. Rapid changes in altitude and gravity, such as those typically found on flight take-off and landing, can affect insulin delivery, leading to possible hypoglycaemia or injury. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within​ clinical practice settings. The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/sscp for complete safety information including indications, contraindications, warnings, cautions, and instructions.Omnipod 5 may not be available in your country.  © Insulet Corporation. All rights reserved. INS-OHS-05-2026-00395 v1.0

  4. 21 Apr

    RADIANT Trial Results: The Impact on Type 1 Diabetes (T1D) Patients and a Glimpse into the Future of Diabetes Care

    What happens when you transition type 1 diabetes (T1D) patients from multiple daily injections (MDI) to Omnipod 5 using Abbott’s Freestyle Libre 2?  That is exactly what the RADIANT Randomized Controlled Trial (RCT) investigated.    Listen to Within Range with Kate Neal, Clinical Services Manager at Insulet who is joined by Dr. Emma Wilmot - Associate Professor at University of Nottingham, consultant Diabetologist, & founder of the Diabetes Technology Network UK - to unpack the incredible results of the RADIANT trial and discuss its impact on patients and the future of diabetes care.  Recently published in The Lancet Diabetes & Endocrinology journal, Dr Emma Wilmot shares not just the results of the RADIANT trial but also how she approaches onboarding her patients with Automated Insulin Delivery (AID), highlighting the importance of peer support, and how she is contributing to reducing the daily burden of those living with type 1 diabetes (t1d).  ---  How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations.  Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D).  If you’re looking to improve your patient’s time in range as well as time in happiness, then this is the podcast for you.  ---  Disclaimer  Note: The information in this podcast is accurate to the date of recording as of 12/03/2024. Dr. Emma Wilmot’s, views and opinions expressed in this podcast are her own and do not necessarily reflect those of Insulet.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety.  For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.  © Insulet Corporation. All rights reserved. INS-OHS-04-2026-00067 v1.0

  5. 17 Mar

    REPLAY: Understanding Omnipod 5: The future of Diabetes Tech

    In our inaugural episode, hosts Kate Neal and Cindy Pickering are joined by Dr Sufyan Hussain, consultant in diabetes, endocrinology and general medicine at Guys and St Thomas’s Hospital in London. Dr Hussain talks about his personal and professional experience with type 1 diabetes and how he has seen technology rapidly evolve over the past decade. He discusses his work as a clinician, helping others to manage diabetes with game-changing results through Omnipod® 5 and the approach to training patients on the Omnipod® 5 System in the UK. He provides practical advice to clinicians and sets expectations for patients just starting out with the technology, and shares case studies where there has been a significant breakthrough in the management of diabetes. Recorded in March 2024. Disclaimer Note: The information in this podcast is accurate to the date of recording as of 27/03/2024. Dr. Sufyan Hussain, interviewed here, received a fee from Insulet for taking part in this podcast. Views and opinions expressed in this podcast are his own and do not necessarily reflect those of Insulet.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5, including indications, contraindications and important safety information for the UK, please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country-specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.  ©2026 Insulet Corporation. All rights reserved. Insulet Netherlands BV, Stadsplateau 7, 3521 AZ Ultrecht, Netherlands INS-OHS-03-2026-00187 v1.0

  6. 17 Feb

    Clinical Data and Practical Experience: The Impact of Omnipod® 5

    For people living with type 1 diabetes, simplifying daily glycaemic management is essential, and Omnipod 5 is helping people do just that.   In this episode of Within Range, host Kate Neal - Clinical Services Manager at Insulet, sits down with Dr Fraser Gibb - Consultant Physician and Diabetologist at Edinburgh Royal Infirmary and Honorary Clinical Reader at the University of Edinburgh, to explore how Omnipod 5’s intuitive technology makes diabetes care more accessible. They highlight how the device’s tubeless design and hybrid closed loop system transform diabetes management, improving outcomes.   This episode of Within Range covers: ·      The simplicity of system setup, the importance of user-initiated boluses, and the personalisation of glucose targets. ·      Practical strategies for initial settings and simple ways to correct high glucose levels. ·      How the PANTHERTOOL® can help with pattern management and optimisation and can be accessed at https://www.omnipod.com/en-gb/hcp/education-training/panther-tool ·      The role of patients in managing their diabetes effectively with technology and clinical support.   Disclaimer Note: The information in this podcast is accurate to the date of recording as of 09/18/2025. Dr. Fraser Gibb, interviewed here, received a fee from Insulet for taking part in this Podcast, views and opinions expressed in this podcast are his own and do not necessarily reflect those of Insulet. When Dr. Gibb refers to HbA1c of 58 mmol/mol this corresponds to an HbA1c of 7.5%. When he refers to an improvement in HbA1c of 9mmol/mol this relates to an improvement of HbA1c of 0.8%.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country. INS-OHS-01-2026-00175 v2.0

  7. 7 Jan

    Is 70% Time in Range really 70% Time in Range? Making Sense of CGM Accuracy and the impact on Automated Insulin Delivery

    Automated insulin delivery (AID) relies on the accuracy of the sensor behind it—so what happens when “70% time in range” doesn’t mean the same thing across different continuous glucose monitoring (CGM) systems? Recorded at EASD in Vienna, this special episode of Within Range brings together clinical, research and real-world perspectives to unpack how CGM accuracy, comparator methods (capillary vs venous) and standardisation efforts shape the numbers healthcare professionals rely on every day. Registered dietitian and diabetes educator John Pemberton uses a powerful “strict vs lenient marker” analogy to explain why identical time in range figures can mask very different glucose exposure—and why pairing CGM metrics with HbA1c remains critical. Then Insulet’s Medical Affairs team sit down with CGM experts Dr Guido Freckmann and Dr Othmar Moser to discuss new data comparing current-generation sensors (including in exercise settings), the push for unified CGM evaluation standards, implications for hybrid closed loop safety, and what health care professionals should consider when interpreting trials, real-world datasets and choosing AID systems with their patients. Who you’ll hear from on this episode: ·     Kate Neal - Clinical Services Manager at Insulet. ·     Irene Hadjiyianni - Director, Medical Affairs Europe at Insulet. ·     Séverine Labat – Senior Director of Medical Affairs at Insulet. ·     John Pemberton – Registered dietitian and diabetes educator, sharing practical insights from supporting approximately 300 children and young people with type 1 diabetes, and how he translates sensor accuracy data into real-world AID decisions. ·     Dr Guido Freckmann – Medical Director, Institute of Diabetes Technology in Germany, outlining a new challenging study procedure for CGM evaluation, key findings on sensor differences, and the drive towards clear accuracy targets. ·     Dr Othmar Moser – Exercise physiology and metabolism expert, presenting data on CGM performance during physical activity, and what accuracy means for safety and trust in automated insulin delivery.   Disclaimer   Note: The information in this podcast is accurate to the date of recording as of 09/17/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.   Clinical data referenced in this episode can be found here: Eichenlaub M et al. Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2025 Feb 4:19322968251315459. doi: 10.1177/19322968251315459. Epub ahead of print. PMID: 39902649; PMCID: PMC11795573.   INS-OHS-11-2025-00087 v1.0

  8. 02/12/2025

    Challenging Bias: Making Diabetes Tech Accessible for Everyone

    Although guidelines are pointing to Automated Insulin Delivery Systems as standard of care for managing type 1 diabetes, not all people are being offered AID as a therapy option. Why are some people still left behind—and what can healthcare professionals do about it? In this episode of Within Range from EASD 2025 in Vienna, host Kate Neal, Clinical Services Manager at Insulet, speaks with Dr. Alice Cheng and Dr. Hood Thabit about how unconscious bias, clinical inertia, and outdated assumptions continue to shape who gets offered diabetes technology. They discuss what happens when healthcare teams assume patients “can’t handle” diabetes tech, how automation is breaking old barriers, and the practical strategies that make access fairer—from embedding technology conversations into every visit to using group starts and peer support to reach underrepresented communities. Who you’ll hear from on this episode: • Dr. Alice Cheng, endocrinologist at Trillium Health Partners, University of Toronto Associate Professor, and creator of the Med Ed Pledge, sharing how simple clinic routines can dismantle unconscious bias and make technology offers equitable. • Dr. Hood Thabit, consultant diabetologist and Senior Lecturer at Manchester University NHS Foundation Trust, explaining how outreach, empathy, and inclusive education can bring marginalized groups into automated insulin delivery programs. Disclaimer Note: The information in this podcast is accurate to the date of recording as of 09/18/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/engb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country. INS-OHS-11-2025-00168 v1.0

See All (20)

Ratings & Reviews

5
out of 5
4 Ratings

About

Within Range is a podcast for Healthcare Professionals. Diabetes tech innovation moves quickly and it can be challenging to keep all the details about the available AID systems straight. Our new podcast, Within Range: Demystifying Diabetes Tech will help bust some myths and clear up any confusion about the Omnipod® 5 Automated Insulin Delivery System. Co-hosts Cindy Pickering & Kate Neal lead conversations with Healthcare Professionals with varying specialties and backgrounds. From clinical research and guidelines, system details, algorithm functionality, to the more practical aspects of helping people live with T1D, you are invited to listen in, while they cover a variety of specialisms. This professional (but entertaining) podcast aims to navigate the complexities of diabetes technology and increase understanding and confidence to help simplify diabetes management for your patients using the Omnipod 5 Automated Insulin Delivery System.

Information

You Might Also Like